Humana Inc.’s Stock Price Plummets to $279.45, Suffers Sharp Decline of 11.77%

Humana Inc. (HUM)

279.45 USD -37.29 (-11.77%) Volume: 7.02M

Humana Inc.’s stock price stands at 279.45 USD, experiencing a significant drop of -11.77% this trading session, with a high trading volume of 7.02M. The healthcare company’s stock has taken a hit YTD, recording a decline of -38.96%, a pivotal point for potential investors looking for investment opportunities in the healthcare sector.

Latest developments on Humana Inc.

Humana Inc. has been making headlines recently with the unveiling of their Medicare Advantage plans for 2025, focusing on quality and affordable healthcare for consumers. Despite this positive news, the company’s stock touched a 52-week low at $298.59 amidst market shifts and underperformed compared to competitors. In a show of philanthropy, the Humana Foundation donated $1 million to support disaster recovery efforts in the aftermath of Hurricane Helene. Looking ahead, investors are eagerly awaiting the release of Humana Inc.’s third quarter 2024 results on October 30, 2024. With the company’s continued focus on innovative healthcare solutions and recent recognition for top telehealth services satisfaction alongside Florida Blue, the future remains promising for Humana Inc.

Humana Inc. on Smartkarma

Analysts on Smartkarma, like Baptista Research, have been closely following Humana Inc. and providing valuable insights into the company’s performance. In a report titled “Humana Inc.: Enhanced Strategic Management of Benefit Costs and Member Acquisition Tactics! – Major Drivers,” analysts noted a mixed set of results for the first quarter of 2024. The company reaffirmed its full-year adjusted EPS guidance and increased its membership growth outlook, showcasing operational resilience and strategic expansions. This positive performance was supported by inline or positive medical cost trends and visible growth in their primary care business.

In another report by Baptista Research, titled “Humana Inc.: Impacts on Pharmacy Benefit Managers (PBMs) Resulting From IRA Changes & Other Major Drivers,” analysts highlighted Humana’s solid start to 2024. The company’s CEO and CFO shared insights during a Q&A session following the earnings call, reaffirming the full-year adjusted earnings per share guidance. These reports provide investors with a comprehensive analysis of Humana Inc.’s financial performance and future outlook, helping them make informed investment decisions.

A look at Humana Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Humana Inc has received a strong overall outlook based on the Smartkarma Smart Scores. With a high Value score, the company is seen as offering good value for investors. While the Dividend, Growth, Resilience, and Momentum scores are not as high, they still indicate positive factors for the company’s long-term prospects. This suggests that Humana Inc may be a solid investment choice for those looking for a company with strong value.

Humana Inc is a managed health care company that operates in the United States and Puerto Rico. The company provides coordinated health care services through various plans and products to a range of customers, including employer groups, government-sponsored plans, and individuals. With its positive Smartkarma Smart Scores, Humana Inc appears to be well-positioned for long-term success in the managed health care industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma